PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $21.00 target price on the stock.

Other analysts also recently issued reports about the stock. B. Riley reduced their target price on shares of PDS Biotechnology from $11.00 to $9.00 and set a buy rating on the stock in a research report on Wednesday, June 12th. Alliance Global Partners raised shares of PDS Biotechnology to a strong-buy rating in a research note on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $14.25.

PDS Biotechnology Stock Performance

Shares of PDSB opened at $3.21 on Tuesday. The company has a 50-day simple moving average of $3.36 and a two-hundred day simple moving average of $3.49. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. The firm has a market capitalization of $117.74 million, a PE ratio of -2.36 and a beta of 1.88. PDS Biotechnology has a one year low of $2.53 and a one year high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same period in the prior year, the business earned ($0.37) EPS. On average, analysts anticipate that PDS Biotechnology will post -1.3 EPS for the current fiscal year.

Institutional Trading of PDS Biotechnology

Institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new position in shares of PDS Biotechnology in the second quarter worth approximately $146,000. Point72 Asia Singapore Pte. Ltd. bought a new position in PDS Biotechnology in the 2nd quarter valued at approximately $115,000. Squarepoint Ops LLC bought a new position in PDS Biotechnology in the 2nd quarter valued at approximately $120,000. Blair William & Co. IL boosted its stake in PDS Biotechnology by 204.4% during the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after purchasing an additional 81,743 shares during the last quarter. Finally, Ground Swell Capital LLC bought a new stake in shares of PDS Biotechnology in the 2nd quarter worth $67,000. 26.84% of the stock is owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.